52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
29
Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Novartis Pharma
6
Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors.
Novartis Institutes For Biomedical Research
7
Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.
University of Michigan
3
Inhibitors of factor d may provide a treatment for age-related macular degeneration.
Therachem Research Medilab (India)
21
Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.
Takeda Pharmaceutical
41
Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives.
Hefei University of Technology
53
Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.
Biocryst Pharmaceuticals
19
Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.
Novartis Institutes For Biomedical Research
18
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.
Taipei Medical University
23
Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.
Novartis Institutes For Biomedical Research
38
Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
Novartis Institutes For Biomedical Research
17
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Novartis Institutes For Biomedical Research
16
Ligand-Based Fluorine NMR Screening: Principles and Applications in Drug Discovery Projects.
Lavis
39
Chemical Approaches to Modulating Complement-Mediated Diseases.
The University of Queensland
18
Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.
Novartis Pharma
199
1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
Merck Sharp & Dohme
42
Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors
Eil Therapeutics
116
Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
Pharmaxis
42
Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
Prelude Therapeutics
22
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
Purdue University
59
Potent and selective inhibitors of monoamine transporters; method of making; and use thereof
Department Of Health And Human Services
31
1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
Respivert
556
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Eli Lilly
37
Inhibition of the alpha- and beta-carbonic anhydrases from the gastric pathogen Helycobacter pylori with anions.
Universit�� Degli Studi Di Firenze
4
Design, Synthesis, and Experimental Validation of Peptide Ligands Targeting Mycobacterium tuberculosis s Factors.
Indian Institute of Science
1
Mechanism of Flavoprotein l-6-Hydroxynicotine Oxidase: pH and Solvent Isotope Effects and Identification of Key Active Site Residues.
University of Texas Health Science Center
16
Methods for increasing the stabilization of hypoxia inducible factor-α
Aerpio Therapeutics
5
Molecular Mechanism for Isoform-Selective Inhibition of Acyl Protein Thioesterases 1 and 2 (APT1 and APT2).
University of Michigan
2
The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.
The Ohio State University
3
Biochemical and structural analysis of an Eis family aminoglycoside acetyltransferase from bacillus anthracis.
University of Kentucky
7
Design and synthesis of paracaseolide A analogues as selective protein tyrosine phosphatase 1B inhibitors.
Lanzhou University
4
Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001.
Taisho Pharmaceutical